Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

What to Do When Patch Testing is Negative?

American Contact Dermatitis Society (ACDS)

M. Montanez-Wiscovich

Experts Discuss Pros and Cons of Treatment Approaches in PV

BMFcases

T. Bat, A. Tefferi

2024 Updates in PV/ET

University of Colorado Division of Hematology

B. McMahon

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

BMFcases

T. Bat, A. Tefferi

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

Ruben Mesa

Review of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Incyte

C. Harrison

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Incyte

C. Harrison

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Indy Hematology Review

R. Rampal

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Implicat…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Experts Address Clinical Questions in PV: Utility of Aspirin, Rusfer…

BMFcases

T. Bat, A. Tefferi

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

R. Mesa

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

When to Switch From Hydroxyurea to Ruxolitinib in PV

Prithviraj Bose